GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiGen Biopharmaceuticals Holdings Ltd (ROCO:4157) » Definitions » EV-to-Revenue

TaiGen Biopharmaceuticals Holdings (ROCO:4157) EV-to-Revenue : 77.55 (As of Jun. 20, 2024)


View and export this data going back to 2013. Start your Free Trial

What is TaiGen Biopharmaceuticals Holdings EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, TaiGen Biopharmaceuticals Holdings's enterprise value is NT$9,883.1 Mil. TaiGen Biopharmaceuticals Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was NT$127.4 Mil. Therefore, TaiGen Biopharmaceuticals Holdings's EV-to-Revenue for today is 77.55.

The historical rank and industry rank for TaiGen Biopharmaceuticals Holdings's EV-to-Revenue or its related term are showing as below:

ROCO:4157' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.67   Med: 244.49   Max: 1139.47
Current: 77.55

During the past 13 years, the highest EV-to-Revenue of TaiGen Biopharmaceuticals Holdings was 1139.47. The lowest was 6.67. And the median was 244.49.

ROCO:4157's EV-to-Revenue is ranked worse than
82.01% of 1034 companies
in the Biotechnology industry
Industry Median: 7.565 vs ROCO:4157: 77.55

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-06-20), TaiGen Biopharmaceuticals Holdings's stock price is NT$15.10. TaiGen Biopharmaceuticals Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was NT$0.18. Therefore, TaiGen Biopharmaceuticals Holdings's PS Ratio for today is 85.80.


TaiGen Biopharmaceuticals Holdings EV-to-Revenue Historical Data

The historical data trend for TaiGen Biopharmaceuticals Holdings's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiGen Biopharmaceuticals Holdings EV-to-Revenue Chart

TaiGen Biopharmaceuticals Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 620.43 685.95 7.85 293.80 80.79

TaiGen Biopharmaceuticals Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 307.10 93.05 80.63 80.79 79.81

Competitive Comparison of TaiGen Biopharmaceuticals Holdings's EV-to-Revenue

For the Biotechnology subindustry, TaiGen Biopharmaceuticals Holdings's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TaiGen Biopharmaceuticals Holdings's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TaiGen Biopharmaceuticals Holdings's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where TaiGen Biopharmaceuticals Holdings's EV-to-Revenue falls into.



TaiGen Biopharmaceuticals Holdings EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

TaiGen Biopharmaceuticals Holdings's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=9883.096/127.436
=77.55

TaiGen Biopharmaceuticals Holdings's current Enterprise Value is NT$9,883.1 Mil.
TaiGen Biopharmaceuticals Holdings's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$127.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TaiGen Biopharmaceuticals Holdings  (ROCO:4157) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

TaiGen Biopharmaceuticals Holdings's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=15.10/0.176
=85.80

TaiGen Biopharmaceuticals Holdings's share price for today is NT$15.10.
TaiGen Biopharmaceuticals Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.18.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TaiGen Biopharmaceuticals Holdings EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of TaiGen Biopharmaceuticals Holdings's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


TaiGen Biopharmaceuticals Holdings (ROCO:4157) Business Description

Traded in Other Exchanges
N/A
Address
No. 138 Xinming Road, 114th Floor, Neihu District, Taipei, TWN, 114
TaiGen Biopharmaceuticals Holdings Ltd is a market-oriented pharmaceutical Research and development company with R and D as the core, committed to the development of anti-infective drugs. The company has a subsidiary in Beijing to conduct clinical trials and registration of new drugs in China.

TaiGen Biopharmaceuticals Holdings (ROCO:4157) Headlines

No Headlines